White House chief medical advisor Dr. Anthony Fauci to step down in December after more than 50 years of public service

White House chief medical advisor Dr. Anthony Fauci to step down in December after more than 50 years of public service


Dr. Anthony Fauci speaks about the Omicron coronavirus variant during a press briefing at the White House in Washington, December 1, 2021.

Kevin Lamarque | Reuters

The nation’s top infectious disease expert, Dr. Anthony Fauci, plans to step down from his roles running the National Institute of Allergy and Infectious Diseases and advising the White House as its chief medical advisor at the end of the year, he announced Monday.

Fauci has become a household fixture during the Covid-19 pandemic, battling back misinformation — sometimes from the highest levels of government. His steadfast commitment to science, challenging former President Donald Trump on everything from the use of  hydroxychloroquine to mask mandates, made him a quasi-celebrity in the process.

The 81-year-old has advised seven U.S. presidents, starting with Ronald Reagan through the HIV/AIDS epidemic, West Nile virus, the 2001 anthrax attacks, pandemic influenza, various bird influenza threats, Ebola, Zika and, most recently, Covid and monkeypox.

Fauci, who also runs the NIAID Laboratory of Immunoregulation, said he has no intentions of retiring.

“After more than 50 years of government service, I plan to pursue the next phase of my career while I still have so much energy and passion for my field,” Fauci said in a statement. “I want to use what I have learned as NIAID Director to continue to advance science and public health and to inspire and mentor the next generation of scientific leaders as they help prepare the world to face future infectious disease threats.”

He first joined the National Institutes of Health in 1968 at age 27 where he quickly rose through the ranks and eventually took over as director of the National Institute of Allergy and Infectious Diseases in 1984.

Fauci didn’t shy away from conflict. His Senate hearings were often peppered with terse exchanges with members of Congress, particularly with Sen. Rand Paul, R-Ky., who he once accused of inciting death threats against him and his family.

“What happens when he gets out and accuses me of things that are completely untrue is that all of a sudden that kindles the crazies out there and I have threats upon my life, harassment of my family and my children with obscene phone calls, because people are lying about me,” Fauci told the Senate health committee at a January hearing.

This is breaking news. Please check back for updates.



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More